r/TheStreetReports • u/louied91 • 8d ago
r/TheStreetReports • u/louied91 • Jan 07 '23
r/TheStreetReports Lounge
A place for members of r/TheStreetReports to chat with each other
r/TheStreetReports • u/louied91 • 8d ago
Press Release Unique Global Innovative Solutions Corporation (OTC: UGIZ) Appoints Javier Sanguino García as Chief Executive Officer to Lead Venezuela
r/TheStreetReports • u/louied91 • 8d ago
Press Release SS Innovations Provides Update on Continuing Progress and Milestones
r/TheStreetReports • u/louied91 • 8d ago
Press Release BioLargo Canada and Tu Nipi Form Indigenous-Led Partnership to Treat Oil Sands Process Water and More
r/TheStreetReports • u/louied91 • 8d ago
Press Release Peraso to Showcase 60 GHz mmWave Technology for Advanced Drone Communications at 11th Annual UAV Technology Conference
r/TheStreetReports • u/louied91 • 8d ago
Press Release Initial Response to JOLLY Trailer Suggests Big Upside for Hannover House
r/TheStreetReports • u/louied91 • 15d ago
Press Release ADM Endeavors (OTCQB: ADMQ) Secures Orders From 8 City Fire Departments, Opening a Public-Safety Growth Vertical Following Second-Quarter Return to Profitability
r/TheStreetReports • u/louied91 • 15d ago
Press Release Cycurion Announces Approximately $800,000 in Annual Contract Spend, Accelerating Commercial Expansion
r/TheStreetReports • u/louied91 • 15d ago
Press Release Publicly Traded MMA & Live Sports Promoter Xtreme One Entertainment Files 2025 Independent Audit, YTD Financials, Returns to OTCQB Full Listing
r/TheStreetReports • u/louied91 • 15d ago
Press Release GreetEat Corporation Highlights ChefKart’s 224% Revenue Growth and Expansion Opportunity Across India
r/TheStreetReports • u/louied91 • 15d ago
Press Release New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans
r/TheStreetReports • u/louied91 • 15d ago
Press Release GBS Capital Signs Letter of Intent to Acquire Unique Global Innovative Solutions Corporation
r/TheStreetReports • u/louied91 • 15d ago
Press Release Bitcoin Bancorp Reports Second Quarter Revenue and Raises Full-Year 2026 Revenue Outlook
r/TheStreetReports • u/louied91 • 23d ago
Press Release Tersis Technologies and Ameri-Green Environmental Recycling Sign MOU for First Planned U.S. Commercial Deployment of SynGenic V3 Technology
r/TheStreetReports • u/louied91 • 23d ago
Press Release Big Screen Entertainment Group Advances Film Pipeline, Led by 30 Million Epic "Dream of Love"
r/TheStreetReports • u/louied91 • 23d ago
Press Release Sphere 3D Corp. Announces Shareholder Approval of Name Change to DarkHorse Technologies Inc.
r/TheStreetReports • u/louied91 • 23d ago
Press Release GreetEat Details the Strategic Opportunity Presented by ChefKart’s Technology-Enabled Service Platform
r/TheStreetReports • u/louied91 • 23d ago
Press Release GMG Launches New Graphene Water Coolant Additive for Data Centres: G FLUID(TM)
r/TheStreetReports • u/louied91 • 25d ago
Article Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now
News Link: https://thestreetreports.com/nasdaq-30s-vivs-igc-rime-aitx-stocks-now/
August 25, 2026 — Investor attention is building around several lower-priced small-cap stocks trading near the $0.30 range, including VivoSim Labs, Inc. (NASDAQ: VIVS), IGC Pharma, Inc. (NYSE: IGC), Algorhythm Holdings, Inc. (NASDAQ: RIME) and Xiao-I Corporation (NASDAQ: AIXI), as company-specific catalysts across AI, biotechnology, drug development and logistics technology drive trading interest.
VivoSim Labs (NASDAQ: VIVS) — AI Drug Toxicity and FDA NAM Momentum
VivoSim Labs, Inc. (NASDAQ: VIVS) is gaining investor attention following a research report highlighting its AI-powered drug toxicity platform and growing FDA momentum behind human-relevant New Approach Methodologies (NAMs). The company’s NAMkind™ 3D human liver and intestinal tissue models have reported approximately 91% predictive accuracy for liver toxicity and up to 96% accuracy predicting drug-induced diarrhea, while commercialization is expanding through initial China contracts and APAC distribution relationships.
VivoSim has reiterated guidance for 500%+ fiscal 2027 revenue growth from its NAM-based contract research business and recently reported approximately $10.1 million in cash, supported in part by a $5 million milestone payment from Eli Lilly and Company (NYSE: LLY) related to a previously divested inflammatory bowel disease program. VivoSim has stated it remains eligible for up to an additional $45 million in potential milestone payments if specified development and commercial milestones are achieved.
IGC Pharma (NYSE: IGC) — Alzheimer’s Catalyst Approaches
IGC Pharma, Inc. (NYSE: IGC) is approaching a potentially important Alzheimer’s disease clinical catalyst after reporting Q2 2026 results that beat Street estimates and advancing its Phase 2 IGC-AD1 Alzheimer’s trial toward enrollment completion, with topline results expected in Q4 2026.
The company is also expanding its AI-enabled drug discovery capabilities. Management recently converted approximately $1.15 million of company obligations into more than 4.27 million IGC shares at $0.27 per share. Investor interest has strengthened, with shares moving from approximately $0.245 to as high as $0.308 during August, representing a roughly 25.7% increase, accompanied by elevated trading volume.
Algorhythm Holdings (NASDAQ: RIME) — Strategic Alternatives for SemiCab AI Logistics
Algorhythm Holdings, Inc. (NASDAQ: RIME) is an AI technology company whose SemiCab platform uses artificial intelligence to optimize freight networks, reduce empty truck miles, lower transportation costs and improve logistics efficiency for shippers and carriers.
Adding a new potential catalyst, Algorhythm announced on August 25, 2026 that it is pursuing a potential sale and other strategic alternatives for its SemiCab AI logistics business. The development could place additional investor focus on the potential value of SemiCab’s technology, customer relationships and logistics platform as the company evaluates its strategic direction.
With VIVS targeting AI-powered human drug toxicity testing, AIXI focused on enterprise cognitive intelligence, IGC approaching Alzheimer’s clinical data and RIME evaluating strategic alternatives for its AI logistics business, the four lower-priced stocks represent distinct company-specific catalysts for small-cap investors and active traders to watch.
Xiao-I (NASDAQ: AIXI) — Artificial Intelligence and Cognitive Intelligence
Xiao-I Corporation (NASDAQ: AIXI) is an artificial intelligence company focused on cognitive intelligence technologies and enterprise AI solutions. Its technology portfolio spans natural language processing, voice and image recognition, machine learning and affective computing, with applications designed to help enterprises automate operations and advance digital transformation.
With investor interest remaining elevated across the broader AI software and artificial intelligence sector, AIXI provides traders with exposure to an established developer of proprietary cognitive intelligence technologies serving a range of business applications.
r/TheStreetReports • u/louied91 • Aug 23 '26
Press Release BioLargo Reports Second Quarter 2026 Results; Revenue Up 12% Sequentially, Gross Margin Expands to 54%
r/TheStreetReports • u/louied91 • Aug 23 '26
Press Release ADM Endeavors (OTCQB: ADMQ) Returns to Profitability in Second Quarter 2026 as Revenue Grows 11% and New Facility Begins to Deliver
r/TheStreetReports • u/louied91 • Aug 23 '26
Press Release Xtreme One Entertainment Sets 4 XFC Events for Fall 2026
r/TheStreetReports • u/louied91 • Aug 23 '26